RESUMO
Accumulating evidence indicates that mesenchymal stem/stromal cell-derived extracellular vesicles (MSC-EVs) exhibit immunomodulatory effects by delivering therapeutic RNAs and proteins; however, the molecular mechanism underlying the EV-mediated immunomodulation is not fully understood. In this study, we found that EVs from early-passage MSCs had better immunomodulatory potency than did EVs from late-passage MSCs in T cell receptor (TCR)- or Toll-like receptor 4 (TLR4)-stimulated splenocytes and in mice with ocular Sjögren's syndrome. Moreover, MSC-EVs were more effective when produced from 3D culture of the cells than from the conventional 2D culture. Comparative molecular profiling using proteomics and microRNA sequencing revealed the enriched factors in MSC-EVs that were functionally effective in immunomodulation. Among them, manipulation of transforming growth factor ß1 (TGF-ß1), pentraxin 3 (PTX3), let-7b-5p, or miR-21-5p levels in MSCs significantly affected the immunosuppressive effects of their EVs. Furthermore, there was a strong correlation between the expression levels of TGF-ß1, PTX3, let-7b-5p, or miR-21-5p in MSC-EVs and their suppressive function. Therefore, our comparative strategy identified TGF-ß1, PTX3, let-7b-5p, or miR-21-5p as key molecules mediating the therapeutic effects of MSC-EVs in autoimmune disease. These findings would help understand the molecular mechanism underlying EV-mediated immunomodulation and provide functional biomarkers of EVs for the development of robust EV-based therapies.
Assuntos
Proteína C-Reativa/genética , Vesículas Extracelulares/transplante , Células-Tronco Mesenquimais/citologia , MicroRNAs/genética , Componente Amiloide P Sérico/genética , Síndrome de Sjogren-Larsson/terapia , Fator de Crescimento Transformador beta1/genética , Animais , Proteína C-Reativa/metabolismo , Técnicas de Cultura de Células , Diferenciação Celular , Proliferação de Células , Células Cultivadas , Modelos Animais de Doenças , Vesículas Extracelulares/genética , Vesículas Extracelulares/metabolismo , Perfilação da Expressão Gênica , Humanos , Células-Tronco Mesenquimais/metabolismo , Camundongos , Proteômica , Inoculações Seriadas , Componente Amiloide P Sérico/metabolismo , Síndrome de Sjogren-Larsson/genética , Síndrome de Sjogren-Larsson/metabolismo , Fator de Crescimento Transformador beta1/metabolismoAssuntos
Neurologia , Síndrome de Sjogren-Larsson/terapia , Pré-Escolar , Imagem de Difusão por Ressonância Magnética , Eletroencefalografia , Humanos , Espectroscopia de Ressonância Magnética , Masculino , Síndrome de Sjogren-Larsson/diagnóstico por imagem , Substância Branca/diagnóstico por imagemRESUMO
Sjögren-Larsson syndrome (SLS) is a congenital ichthyotic disorder with spasticity. We describe a case of a 5-year-old boy with SLS diagnosed clinically based on congenital ichythosis, quadriplegia, and mental retardation. The child responded well to emollients and antihistamines. His quadriplegia was managed by aggressive physiotherapy and mental retardation by stimulation techniques. After a 3-year follow up, significant improvement was seen in his motor and mental disability. This case highlights the importance of clinical diagnosis and early intervention for such a disabling disorder.
Assuntos
Modalidades de Fisioterapia , Quadriplegia/terapia , Síndrome de Sjogren-Larsson/diagnóstico , Síndrome de Sjogren-Larsson/terapia , Pré-Escolar , Diagnóstico Precoce , Emolientes/uso terapêutico , Antagonistas dos Receptores Histamínicos/uso terapêutico , Humanos , Deficiência Intelectual/diagnóstico , Deficiência Intelectual/terapia , Masculino , Espasticidade Muscular/diagnóstico , Espasticidade Muscular/terapia , Síndrome de Sjogren-Larsson/patologia , Resultado do TratamentoRESUMO
This review article gives a state-of-the-art synopsis of current pathophysiological concepts in Sjögren-Larsson syndrome (SLS) mainly based upon original research data of the authors in one of the world's largest clinical SLS study cohorts. Clinical features are discussed in order of appearance, and diagnostic tests are set out to guide the clinician toward the diagnosis SLS. Furthermore, current and future treatment strategies are discussed to render a comprehensive review of the topic.
Assuntos
Síndrome de Sjogren-Larsson , Aldeído Oxirredutases/deficiência , Aldeído Oxirredutases/genética , Bezafibrato/uso terapêutico , Encéfalo/patologia , Encéfalo/fisiopatologia , Carotenoides/uso terapêutico , Olho/patologia , Feminino , Terapia Genética , Humanos , Recém-Nascido , Masculino , Mutação , Gravidez , Nascimento Prematuro , Síndrome de Sjogren-Larsson/diagnóstico , Síndrome de Sjogren-Larsson/genética , Síndrome de Sjogren-Larsson/fisiopatologia , Síndrome de Sjogren-Larsson/terapia , Pele/patologiaRESUMO
Sjögren-Larsson syndrome (SLS) is a recessively inherited disease with congenital ichthyosis, spastic diplegia or tetraplegia and mental retardation, caused by a deficiency of fatty aldehyde dehydrogenase. The aim of this study was to examine all 34 Swedish patients with SLS, emphasizing skin symptoms, dermatological treatment, and neurological symptoms (evaluated in some cases for more than 25 years by one and the same investigator). Structured interviews were conducted with the patients and their close relatives. All patients had generalized ichthyosis. The degree of scaling varied markedly inter-individually from moderate to severe, but there was no obvious change with age. Most patients had pruritus, suffered from hypohidrosis, and had palmo-plantar keratoderma. Nineteen patients (56%) were on oral acitretin and all patients were using some type of topical therapy. Motor disability with spasticity and muscular paresis was most pronounced in the legs and fairly slight in the arms. Twenty patients (59%) were dependent on a wheelchair for mobility. Poor blood circulation in the lower legs and oedematous feet were frequently found in adults. All patients had learning disability, which varied from slight to pronounced and was expressed in their speech disorders. Thirteen patients (38%) were being treated medically for epilepsy and all had photophobia. In conclusion, SLS is a chronic, severely disabling neurocutaneous disease in which optimal dermatological therapy is essential to relieve at least the patient's ichthyosis problem.
Assuntos
Síndrome de Sjogren-Larsson/fisiopatologia , Síndrome de Sjogren-Larsson/terapia , Acitretina/uso terapêutico , Adulto , Idoso , Feminino , Humanos , Ictiose/terapia , Entrevistas como Assunto , Ceratolíticos/uso terapêutico , Deficiências da Aprendizagem/complicações , Masculino , Pessoa de Meia-Idade , Dermatopatias/tratamento farmacológico , Distúrbios da Fala/complicações , SuéciaRESUMO
A review is presented of the major clinical features of a number of glycolipidoses including Fabry, Gaucher, Tay-Sachs, metachromatic leukodystrophy as well as CeroidLipofucinosis and Sjogren-Larsson syndrome. The possibilities offered by lipidomics for diagnosis and follow-up after enzyme replacement therapy are presented from a practical perspective. The contribution of HPLC coupled with tandem mass spectrometry has considerably simplified the detection and assay of abnormal metabolites. Corresponding internal standards consisting of weighed mixtures of the stable-isotope labeled metabolites required to calibrate and quantitate lipid components of these orphan diseases standards have yet to become commercially available. A lipidomics approach has been found to compare favorably with DNA-sequence analysis for the rapid diagnosis of pre-birth syndromes resulting from these multiple gene defects. The method also seems to be suitable for screening applications in terms of a high throughput combined with a low rate of false diagnoses based on the wide differences in metabolite concentrations found in affected patients as compared with normal subjects. The practical advantages of handling samples for lipidomic diagnoses as compared to enzyme assay are presented for application to diagnosis during pregnancy.
Assuntos
Terapia Enzimática , Genômica/métodos , Lipidoses/diagnóstico , Lipídeos/química , Doença de Fabry/diagnóstico , Doença de Fabry/fisiopatologia , Doença de Fabry/terapia , Doença de Gaucher/diagnóstico , Doença de Gaucher/fisiopatologia , Doença de Gaucher/terapia , Humanos , Leucodistrofia Metacromática/diagnóstico , Leucodistrofia Metacromática/fisiopatologia , Leucodistrofia Metacromática/terapia , Lipidoses/enzimologia , Lipidoses/terapia , Lipofuscinoses Ceroides Neuronais/diagnóstico , Lipofuscinoses Ceroides Neuronais/fisiopatologia , Lipofuscinoses Ceroides Neuronais/terapia , Síndrome de Sjogren-Larsson/diagnóstico , Síndrome de Sjogren-Larsson/fisiopatologia , Síndrome de Sjogren-Larsson/terapia , Doença de Tay-Sachs/diagnóstico , Doença de Tay-Sachs/fisiopatologia , Doença de Tay-Sachs/terapiaRESUMO
Sjögren-Larsson syndrome is a recessively inherited syndrome caused by deficiency of fatty aldehyde dehydrogenase. The most common symptoms and signs are described, especially ichthyosis, spastic diplegia, and severe learning difficulties; but also other less frequent ones. Special investigations include sensory evoked potentials, electromyography, and proton magnetic resonance spectroscopy. Post-mortem examination shows, in particular, an accumulation of lipid substances in specific regions of the brain. The diagnosis depends on the measurement of fatty aldehyde dehydrogenase in cultured fibroblasts from skin biopsies, and by identifying known mutations by allele-specific polymerase chain reaction assay. Prenatal diagnosis is possible by using the same technique. The disorder is located on gene 17, and many mutations have been identified. Most mutations are unique to an affected family, but clinical variations may be due to unknown genetic and environmental factors. The deficiency of the enzyme impairs the oxidation of medium and long chain fatty aldehydes, and this may explain the link between the brain and skin disorders. The treatment of affected children needs input from a number of specialists, and their contributions are discussed.
Assuntos
Síndrome de Sjogren-Larsson , Humanos , Síndrome de Sjogren-Larsson/genética , Síndrome de Sjogren-Larsson/patologia , Síndrome de Sjogren-Larsson/terapiaRESUMO
Sjögren-Larsson syndrome (SLS) is an inherited neurocutaneous disorder caused by mutations in the ALDH3A2 gene that encodes fatty aldehyde dehydrogenase (FALDH), an enzyme that catalyzes the oxidation of fatty aldehyde to fatty acid. Affected patients display ichthyosis, mental retardation and spastic diplegia. More than 70 mutations in ALDH3A2 have been discovered in SLS patients including amino acid substitutions, deletions, insertions and splicing errors. Most mutations are private, but several common mutations reflect founder effects, consanguinity or recurrent mutational events. FALDH oxidizes fatty aldehyde substrates arising from metabolism of fatty alcohols, leukotriene B4, ether glycerolipids and other potential sources such as sphingolipids. The pathogenesis of the cutaneous and neurologic symptoms is thought to result from abnormal lipid accumulation in the membranes of skin and brain; the formation of aldehyde Schiff base adducts with amine-containing lipids or proteins; or defective eicosanoid metabolism. Therapeutic approaches are being developed to target specific metabolic defects associated with FALDH deficiency or to correct the genetic defect by gene transfer.
Assuntos
Aldeído Oxirredutases/deficiência , Aldeído Oxirredutases/genética , Síndrome de Sjogren-Larsson/enzimologia , Síndrome de Sjogren-Larsson/genética , Aldeído Oxirredutases/metabolismo , Humanos , Metabolismo dos Lipídeos , Síndrome de Sjogren-Larsson/diagnóstico , Síndrome de Sjogren-Larsson/terapiaRESUMO
Sjögren-Larsson syndrome (SLS) is an autosomal recessive neurocutaneous disorder caused by mutation in the ALDH3A2 gene that codes for human fatty aldehyde dehydrogenase (FALDH). Sjögren-Larsson syndrome patients lack FALDH, which catalyzes the oxidation of long-chain aliphatic aldehydes to fatty acids. The impaired FALDH activity leads to congenital ichthyosis, mental retardation and spasticity. The current lack of treatment is an impetus to develop gene therapy strategies by introducing functional FALDH into defective cells. We delivered human FALDH into keratinocytes of SLS patients using recombinant adeno-associated virus-2 vectors. Transduction of SLS keratinocytes resulted in an augmentation of FALDH activity comparable to phenotypically normal heterozygous carriers. Toxicity of long-chain aldehydes for FALDH-deficient cells decreased almost to the level of unaffected keratinocytes. Three-dimensional culture of corrected SLS keratinocytes revealed an ameliorated FALDH expression. These studies demonstrate the restoration of FALDH in human SLS cells supporting the concept of gene therapy as a potential future treatment option for SLS.
Assuntos
Aldeído Oxirredutases/deficiência , Aldeído Oxirredutases/genética , Terapia Genética/métodos , Queratinócitos/enzimologia , Síndrome de Sjogren-Larsson/terapia , Aldeído Oxirredutases/análise , Células Cultivadas , Colorimetria , Dependovirus/genética , Engenharia Genética , Vetores Genéticos/administração & dosagem , Humanos , Síndrome de Sjogren-Larsson/enzimologia , Pele/enzimologia , Técnicas de Cultura de TecidosRESUMO
Sjogren-Larsson Syndrome (SLS) is caused by an autosomal recessive defect in the gene coding for fatty aldehyde dehydrogenase (FALDH), an enzyme necessary for the oxidation of long-chain aliphatic aldehydes to fatty acid as one enzyme of the fatty alcohol:nicotinamide-adenine dinucleotide (NAD+)-oxidoreductase complex (FAO). The impaired activity of FALDH leads to the clinical symptom triad of generalized ichthyosis, mental retardation, and spastic diplegia or tetraplegia. Treatment options are primarily symptomatic. Gene therapy by means of genetic reintroduction of the functional FALDH gene into defective cells has so far not been considered as a therapeutic modality. In order to pursue such an approach for SLS, we constructed a recombinant adeno-associated virus-2 vector containing the human cDNA of functional FALDH and evaluated its capability to restore the enzyme-deficiency in a FALDH-deficient cell line resembling the gene defect of SLS. rAAV-2 transduction of FALDH-deficient cells, usually exhibiting less than 10% of normal FALDH activity, resulted in an increase of FALDH activity within the range of unaffected cells. Moreover, FALDH-transduced cells regained resistance over exposure to long chain aldehydes, which are otherwise toxic to FALDH-deficient cells. These results indicated that rAAV-2 vectors are able to restore FALDH-deficiency in a cell system resembling SLS. The findings give the first support to the concept that gene therapy might be a future option for the treatment of SLS.
Assuntos
Aldeído Oxirredutases/genética , Dependovirus/genética , Terapia Genética , Síndrome de Sjogren-Larsson/terapia , Aldeído Oxirredutases/deficiência , Animais , Células CHO , Cricetinae , Vetores Genéticos , Humanos , Síndrome de Sjogren-Larsson/enzimologiaRESUMO
UNLABELLED: Sjögren' Syndrome (SS), also named Sicca Syndrome, is a complex disease, characterized by a series of clinical symptoms and signs chiefly represented by xerostomia, xerophthalmia and connectival diseases. The pathogenetic mechanisms consist of an autoimmune process leading to salivary and lacrimal glands progressive destruction. There is a primary form with salivary and lacrimal glands compromission only and a second form in which xerostomia and/or xerophthalmia are associated with connectival diseases like rheumatoid arthritis, systemic lupus erythematosus and scleroderma. The diagnosis of SS is rather difficult and it is based on various world-wide established and accepted criteria: the labial minor salivary glands biopsy and the research of specific seric autoantibodies are the basic elements. From the therapeutic point of view, various types of immunomodulant treatments based on cyclosporine, corticosteroids, methotrexate or alpha-interferon have been proposed with different RESULTS: Cholinergic drugs, like pilocarpine and cevimeline, are also used in order to stimulate the gland functionality.
Assuntos
Síndrome de Sjogren-Larsson , Diagnóstico Diferencial , Humanos , Síndrome de Sjogren-Larsson/complicações , Síndrome de Sjogren-Larsson/diagnóstico , Síndrome de Sjogren-Larsson/etiologia , Síndrome de Sjogren-Larsson/terapiaAssuntos
Doença , Doença Antimembrana Basal Glomerular/fisiopatologia , Doença Antimembrana Basal Glomerular/terapia , Artrite/fisiopatologia , Artrite/terapia , Humanos , Lúpus Eritematoso Sistêmico/fisiopatologia , Lúpus Eritematoso Sistêmico/terapia , Escleroderma Sistêmico/fisiopatologia , Escleroderma Sistêmico/terapia , Síndrome de Sjogren-Larsson/fisiopatologia , Síndrome de Sjogren-Larsson/terapia , Vasculite/fisiopatologia , Vasculite/terapiaRESUMO
Congenital synspondylism is a recently described condition characterized by short stature, an unusual constellation of vertebral fusions without rib anomalies and carpal coalition. A new case is described to illustrate the diagnostic features and the orthopaedic problems associated with this rare syndrome. Review of available literature shows that patients with congenital synspondylism commonly develop spinal deformity and mild respiratory compromise.